Compare Novartis AG (NVS) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Charles Schwab Corporation Common Stock — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Charles Schwab Corporation Common Stock trades at $100.2 (market cap $178.33B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | SCHW | |
|---|---|---|
Market Cap | $290.25B | $178.33B |
Sector | Health | Financials |
52-Week High | $168.62 | $107.21 |
52-Week Low | $113.50 | $85.35 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Charles Schwab (SCHW) trades at $99.96, down 1.58% on the day, amid strong fundamentals including a 37.99% net income margin and 21.79% ROE. The stock exhibits a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.53 estimated, driven by record revenue and client asset growth. Analyst consensus is bullish with a $120 price target, reflecting 20% upside potential.
Outlook remains positive given consistent earnings beats and robust cash flow, though risks include interest rate sensitivity and competitive pressures. The stock's current valuation at a P/E of 20.39 appears reasonable relative to growth, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
